Immunocore Holdings ADS

At the Morgan Stanley Global Healthcare Conference, Immunocore showcased KIMMTRAK’s commercial strength with over 70% market penetration in core markets and around 1,000 patients treated, and reported a cash balance of $880m. Three Phase III studies (TEBE‑AM, PRISM‑MEL‑301, ATOM) are seen as the next near‑term growth drivers; the company is also working on PRAME programs and expanding the ImmTAC platform into type 1 diabetes and HIV. Management emphasized hard‑to‑replicate science, real‑world data and disciplined capital allocation to fund commercialization, late‑stage trials and early research; a positive study result could substantially expand the addressable market. » Plus sur de.investing.com

Immunocore said at a health conference that KIMMTRAK generated about $220m in H1 2026 (annualized >$400m) and the company has cash and equivalents of $880m; on a quarterly basis it is operating close to breakeven. Management stressed that KIMMTRAK is established as a first‑line standard in key markets, but growth is slowing and first competition is expected within a year. Three phase‑III studies (TEBE‑AM, ADAM, PRISM‑MEL‑301) are expected to deliver important data in the next 2–3 years; additionally, Immunocore is advancing early‑stage programs (Brenetafusp, PRAME, PIWIL1) and a type‑1 diabetes project to validate the platform beyond oncology. » Plus sur de.investing.com

Immunocore reported updated Phase 1/2 results showing brenetafusp monotherapy achieved a 6-month overall survival rate of 87% and a disease control rate of 52% in HLA-A*02:01-positive heavily pretreated melanoma patients. Management said responses and survival were consistent across difficult subgroups, including primary PD-1–resistant patients. The company highlighted confidence in brenetafusp 160 mcg combined with nivolumab in the ongoing Phase 3 PRISM-MEL-301 trial. » Plus sur finance.yahoo.com